Michael Niedbala
Executive Director, Early Oncology Projects AstraZeneca
Seminars
Wednesday 17th September 2025
TRACK A: Drug Discovery & Preclinical Development
Optimizing Small Molecule Inhibitors for More Selective & Potent Therapeutics to Treat KRAS-Mutant Cancers
Wednesday 17th September 2025
AZD0022: a Potent, Oral KRASG12D-Selective inhibitor that Drives Robust Anti-Tumor Activity in KRASG12D Models
12:00 pm
- Disclosure of AZD0022 as a potent, selective, oral KRASG12D inhibitor which inhibits GDP- and GTP- bound KRASG12D
- AZD0022 drives robust RAS pathway inhibition in vitro and in vivo and displays significant antitumour activity in NSCLC, CRC and PDAC pre-clinical models
- These preclinical data are supportive of the ongoing ALAFOSS-1 Ph1/2 Clinical trial initiated in 2024 in NSCLC, CRC and PDAC patients
